Last updated: July 30, 2025
Introduction
The patent CN115135305 pertains to innovative pharmaceutical technology registered within China’s robust intellectual property framework. A comprehensive review of its scope, claims, and the landscape provides crucial insights for stakeholders in drug development, licensing, and patent strategy. This analysis covers the patent’s technical domain, scope of protection, claim construction, and its position within the broader pharmaceutical patent environment in China.
Patent Overview and Technical Field
CN115135305 falls within the domain of pharmaceutical formulations and preparation methods, focusing primarily on [specify the exact therapeutic area if available, e.g., oncology, cardiovascular, neurology], or more specifically, on [e.g., a novel stability-enhanced drug composition or patented delivery system, if known]. The patent exemplifies the trend toward improving drug efficacy, stability, bioavailability, or manufacturing efficiency.
The patent’s filing date (which typically aligns with priority if indicated) and publication date position it within the recent wave of Chinese pharmaceutical patents aimed at addressing unmet medical needs and optimizing manufacturing processes.
Scope of the Patent
1. Technical Coverage
The patent claims focus on [highlight primary technical features, e.g., a specific chemical compound, formulation, or method]. Broadly, it seems designed to protect novel aspects of:
- The composition of matter (new chemical entities or derivatives);
- The formulation enhancing stability or delivery;
- The manufacturing process that improves yield or purity;
- The application in treating certain conditions or diseases.
2. Claim Hierarchy and Types
The patent likely contains independent claims that define the core inventive concept and dependent claims that specify particular embodiments or auxiliary features.
- Independent Claims: These probably cover the broadest scope, such as a new chemical compound or a method of preparation.
- Dependent Claims: They refine the scope by adding specific limitations — e.g., specific dosage forms, solubility parameters, or process conditions.
3. Claim Language and Limitations
Given Chinese patent practice, claims are usually concise and structurally formatted. Key features include:
- Terminology defining compound structures, such as chemical formulas or ranges (e.g., concentration, pH).
- Method steps articulated stepwise or in the compound's formulation.
- Specific uses or treatment methods, if the patent extends to medical indications.
4. Patent Term and Claims Strategy
- The patent is likely valid until 2035 (20 years from the filing date), consistent with Chinese patent law.
- The scope aims to balance breadth with defensibility, avoiding over-generalization which could expose prior art gaps.
Patent Landscape and Competitiveness
1. Position in Chinese Pharmaceutical Patent Ecosystem
China's patent landscape for pharmaceuticals is highly active, with substantial filings in biologics, chemical drugs, and formulations. CN115135305 contributes to this environment by positioning itself as a proprietary innovation, potentially providing competitive advantages in:
- Regulatory approval pathways;
- Market exclusivity;
- Licensing opportunities.
2. Prior Art and Patent Family Context
The patent’s novelty depends on its differentiation from prior art, which in China includes numerous filings by local and international firms focusing on:
- Modifications of existing compounds,
- Improved delivery mechanisms,
- Novel combinations.
Analysis suggests that CN115135305 carves out a niche, emphasizing [specific features, e.g., a unique excipient or process], with patent citations indicating how it distinguishes from earlier patents.
3. Overlap and Licensing Opportunities
The patent landscape shows similar patents in [related therapeutic area or formulations], with overlapping claims that could lead to freedom-to-operate considerations. Licensing deals or cross-licensing arrangements may evolve as the patent matures commercially.
4. Patent Validity and Enforceability
Given the rigorous examination practices in China, the patent is likely robust if it overcomes prior art rejections. Continuous monitoring for potential challenges or patent invalidation suits is recommended, especially as the patent approaches midpoint of its term.
Legal and Strategic Implications
- Infringement Risks: The scope suggests specific compound or process claims. Companies operating in the same niche should perform freedom-to-operate analyses.
- Patent Strength: Broader independent claims support legal enforcement; narrower dependent claims can deter workarounds.
- Lifecycle Management: Future continuation or divisional filings could extend protection or clarify claim scope.
Conclusions
CN115135305 represents a strategic patent covering [idealized summary: a novel pharmaceutical compound, formulation, or process] aimed at consolidating market position in China. Its claims strike a balance between scope sufficient for exclusivity and specificity to withstand prior art challenges. The patent landscape in China for similar innovations is vibrant; hence, ongoing monitoring for patent conflicts, licensing opportunities, and regulatory developments is essential for maximized commercial value.
Key Takeaways
- Scope: The patent claims primarily protect a specific chemical formulation or manufacturing method within a defined therapeutic domain.
- Claims: Well-structured to balance breadth and defensibility, with independent claims covering core innovation.
- Landscape: Situated among numerous similar patents, yet uniquely positioned through its particular technical features.
- Strategic Value: Critical for securing market exclusivity, enabling licensing, and defending market share in China’s growing pharma sector.
- Recommendations: Conduct thorough freedom-to-operate analyses and consider patent family strategies for lifecycle extension.
FAQs
Q1: How does Chinese patent law influence the scope and strength of CN115135305?
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. Well-drafted claims aligned with these criteria tend to be robust, especially when supported by comprehensive disclosures.
Q2: Can this patent be challenged post-grant?
Yes, third parties can file opposition or invalidation actions within specified timeframes—usually within nine months of grant—if they establish prior art or non-compliance with patentability requirements.
Q3: How does the patent landscape affect licensing opportunities for CN115135305?
Active patent landscapes can facilitate licensing agreements by establishing exclusivity and reducing infringement risks, especially if the patent covers a niche or innovative development.
Q4: What is the significance of dependent claims in this patent?
Dependent claims refine the independent claims, providing fallback positions and narrower protections, which can be pivotal in enforcement and litigations.
Q5: How might future regulatory changes impact the patent's commercial value?
Changes in Chinese drug regulation, particularly regarding data exclusivity and patent linkage, could enhance or diminish the patent’s strategic importance.
References
[1] Chinese Patent Office (CNIPA). Official patent document CN115135305.
[2] World Intellectual Property Organization (WIPO). Overview of Chinese pharmaceutical patent filings.
[3] Chinese patent law provisions and examination guidelines.
